253 related articles for article (PubMed ID: 30244085)
1. Galactosylated chitosan triptolide nanoparticles for overcoming hepatocellular carcinoma: Enhanced therapeutic efficacy, low toxicity, and validated network regulatory mechanisms.
Zhang YQ; Shen Y; Liao MM; Mao X; Mi GJ; You C; Guo QY; Li WJ; Wang XY; Lin N; Webster TJ
Nanomedicine; 2019 Jan; 15(1):86-97. PubMed ID: 30244085
[TBL] [Abstract][Full Text] [Related]
2. Triptolide-loaded nanoparticles targeting breast cancer in vivo with reduced toxicity.
Zheng W; Wang C; Ding R; Huang Y; Li Y; Lu Y
Int J Pharm; 2019 Dec; 572():118721. PubMed ID: 31626922
[TBL] [Abstract][Full Text] [Related]
3. Comparison of toxicokinetic and tissue distribution of triptolide-loaded solid lipid nanoparticles vs free triptolide in rats.
Xue M; Zhao Y; Li XJ; Jiang ZZ; Zhang L; Liu SH; Li XM; Zhang LY; Yang SY
Eur J Pharm Sci; 2012 Nov; 47(4):713-7. PubMed ID: 22677813
[TBL] [Abstract][Full Text] [Related]
4. Triptolide-nanoliposome-APRPG, a novel sustained-release drug delivery system targeting vascular endothelial cells, enhances the inhibitory effects of triptolide on laser-induced choroidal neovascularization.
Lai K; Li Y; Gong Y; Li L; Huang C; Xu F; Zhong X; Jin C
Biomed Pharmacother; 2020 Nov; 131():110737. PubMed ID: 32932044
[TBL] [Abstract][Full Text] [Related]
5. Homotypic cell membrane-camouflaged biomimetic PLGA nanoparticle loading triptolide for the treatment of hepatocellular carcinoma.
Li Z; Lan J; Wu Y; Ding Y; Zhang T
Drug Deliv; 2024 Dec; 31(1):2354687. PubMed ID: 38823413
[TBL] [Abstract][Full Text] [Related]
6. Triptolide-targeted delivery methods.
Xu H; Liu B
Eur J Med Chem; 2019 Feb; 164():342-351. PubMed ID: 30605832
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of Cancer Angiogenesis Using Triptolide Nanoparticles.
Wang C; Shan Y; Yang J; Xu X; Zhuang B; Fan Y; Xu W
J Biomed Nanotechnol; 2015 May; 11(5):805-15. PubMed ID: 26349393
[TBL] [Abstract][Full Text] [Related]
8. Combination of metronomic administration and target delivery strategies to improve the anti-angiogenic and anti-tumor effects of triptolide.
Cai XJ; Fei WD; Xu YY; Xu H; Yang GY; Cao JW; Ni JJ; Wang Z
Drug Deliv Transl Res; 2020 Feb; 10(1):93-107. PubMed ID: 31418132
[TBL] [Abstract][Full Text] [Related]
9. Fabrication of a triptolide-loaded and poly-γ-glutamic acid-based amphiphilic nanoparticle for the treatment of rheumatoid arthritis.
Zhang L; Chang J; Zhao Y; Xu H; Wang T; Li Q; Xing L; Huang J; Wang Y; Liang Q
Int J Nanomedicine; 2018; 13():2051-2064. PubMed ID: 29670349
[TBL] [Abstract][Full Text] [Related]
10. Membrane protein-chimeric liposome-mediated delivery of triptolide for targeted hepatocellular carcinoma therapy.
Zheng Y; Kong F; Liu S; Liu X; Pei D; Miao X
Drug Deliv; 2021 Dec; 28(1):2033-2043. PubMed ID: 34569906
[TBL] [Abstract][Full Text] [Related]
11. Kidney-targeted triptolide-encapsulated mesoscale nanoparticles for high-efficiency treatment of kidney injury.
Deng X; Zeng T; Li J; Huang C; Yu M; Wang X; Tan L; Zhang M; Li A; Hu J
Biomater Sci; 2019 Dec; 7(12):5312-5323. PubMed ID: 31617509
[TBL] [Abstract][Full Text] [Related]
12. Novel CD44-targeting and pH/redox-dual-stimuli-responsive core-shell nanoparticles loading triptolide combats breast cancer growth and lung metastasis.
Shi J; Ren Y; Ma J; Luo X; Li J; Wu Y; Gu H; Fu C; Cao Z; Zhang J
J Nanobiotechnology; 2021 Jun; 19(1):188. PubMed ID: 34162396
[TBL] [Abstract][Full Text] [Related]
13. Development of triptolide-nanoemulsion gels for percutaneous administration: physicochemical, transport, pharmacokinetic and pharmacodynamic characteristics.
Yang M; Gu Y; Yang D; Tang X; Liu J
J Nanobiotechnology; 2017 Dec; 15(1):88. PubMed ID: 29202753
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and tissue distribution study in mice of triptolide-loaded lipid emulsion and accumulation effect on pancreas.
Li X; Mao Y; Li K; Shi T; Yao H; Yao J; Wang S
Drug Deliv; 2016 May; 23(4):1344-54. PubMed ID: 25853479
[TBL] [Abstract][Full Text] [Related]
15. pH-sensitive nanoformulated triptolide as a targeted therapeutic strategy for hepatocellular carcinoma.
Ling D; Xia H; Park W; Hackett MJ; Song C; Na K; Hui KM; Hyeon T
ACS Nano; 2014 Aug; 8(8):8027-39. PubMed ID: 25093274
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of triptolide-loaded micelles on tumorigenicity inhibition of human ovarian cancer.
Wang Y; Liu T; Li H
J Biomater Sci Polym Ed; 2016; 27(7):545-56. PubMed ID: 26786618
[TBL] [Abstract][Full Text] [Related]
17.
Sun R; Fang L; Lv X; Fang J; Wang Y; Chen D; Wang L; Chen J; Qi Y; Tang Z; Zhang J; Tian Y
Drug Deliv; 2021 Dec; 28(1):2071-2084. PubMed ID: 34595970
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumour and immuno-modulation effects of triptolide-loaded polymeric micelles.
Xu L; Chen H; Xu H; Yang X
Eur J Pharm Biopharm; 2008 Nov; 70(3):741-8. PubMed ID: 18761405
[TBL] [Abstract][Full Text] [Related]
19. Norcantharidin-associated galactosylated chitosan nanoparticles for hepatocyte-targeted delivery.
Wang Q; Zhang L; Hu W; Hu ZH; Bei YY; Xu JY; Wang WJ; Zhang XN; Zhang Q
Nanomedicine; 2010 Apr; 6(2):371-81. PubMed ID: 19699319
[TBL] [Abstract][Full Text] [Related]
20. Toward targeted therapy in chemotherapy-resistant pancreatic cancer with a smart triptolide nanomedicine.
Wang C; Liu B; Xu X; Zhuang B; Li H; Yin J; Cong M; Xu W; Lu A
Oncotarget; 2016 Feb; 7(7):8360-72. PubMed ID: 26840019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
